TNF and inflammatory bowel disease: The availability of anti-tumor necrosis factor-α (TNF-α) monoclonal antibodies such as infliximab (IFX) has significantly improved the outcome of Crohn’s disease (CD), an inflammatory bowel disease (IBD) that destroys gastrointestinal tissue.